Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science

Annu Rev Biomed Eng. 2021 Jul 13;23:493-516. doi: 10.1146/annurev-bioeng-122019-121602. Epub 2021 Apr 28.


The recent discovery and subsequent development of the CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat-CRISPR-associated protein 9) platform as a precise genome editing tool have transformed biomedicine. As these CRISPR-based tools have matured, multiple stages of the gene editing process and the bioengineering of human cells and tissues have advanced. Here, we highlight recent intersections in the development of biomaterials and genome editing technologies. These intersections include the delivery of macromolecules, where biomaterial platforms have been harnessed to enable nonviral delivery of genome engineering tools to cells and tissues in vivo. Further, engineering native-like biomaterial platforms for cell culture facilitates complex modeling of human development and disease when combined with genome engineering tools. Deeper integration of biomaterial platforms in these fields could play a significant role in enabling new breakthroughs in the application of gene editing for the treatment of human disease.

Keywords: CRISPR; biomaterials; cell therapy; epigenome editing; gene therapy; genome editing; organoids.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biocompatible Materials
  • CRISPR-Cas Systems* / genetics
  • Gene Editing*
  • Humans


  • Biocompatible Materials